Keyphrases
Advanced Biliary Tract Cancer
100%
Biliary Cancer
60%
Dose Reduction
20%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
20%
EGFR Blockade
20%
EGFR Expression
40%
Epidermal Growth Factor Receptor
20%
Erlotinib
100%
Group Classification
20%
HER1
40%
Human Epidermal Growth Factor Receptor
20%
Immunohistochemistry
20%
Ligand-receptor Binding
20%
Locoregional Therapy
20%
Metastatic Disease
20%
Partial Response
20%
Phase II Study
100%
Prior Chemotherapy
20%
Progression-free
40%
Receptor 1
20%
Resectable Disease
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Skin Rash
40%
Systemic Therapy
20%
Targeted Agents
20%
Therapeutic Benefits
20%
Tumor Cells
20%
Tumoral
20%
Worse Outcome
20%
Medicine and Dentistry
Bile Duct Cancer
100%
Diseases
16%
Drug Dose Reduction
16%
Epidermal Growth Factor Receptor
83%
Erlotinib
100%
Exanthem
33%
Gamma Urogastrone
16%
Immunohistochemistry
16%
Metastatic Carcinoma
16%
Oncology
16%
Patient History of Chemotherapy
16%
Progression Free Survival
33%
Response Evaluation Criteria in Solid Tumors
16%
Tumor Cell
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Duct Cancer
100%
Diseases
16%
Epidermal Growth Factor Receptor
83%
Erlotinib
100%
Gamma Urogastrone
16%
Metastasis
16%
Neoplasm
16%
Patient History of Chemotherapy
16%
Progression Free Survival
33%
Rash
33%
Solid Malignant Neoplasm
16%